NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis

Journal of Orthopaedic Research

Volumn 26, Issue 12, 2008, Pages 1577-1584

  Yamanaka, Yasuhiro ^a,b   Abu Amer, Wahid ^a   Foglia, Dominica ^a   Otero, Jesse ^a   Clohisy, John C ^a   Abu Amer, Yousef ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

JNK; NFAT; Osteoclasts; PMMA

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; POLY(METHYL METHACRYLATE); STRESS ACTIVATED PROTEIN KINASE; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; IMPLANTATION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PARTICULATE MATTER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLOSPORINE; DNA; IMMUNOSUPPRESSIVE AGENTS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OLIGOPEPTIDES; OSTEOCLASTS; OSTEOLYSIS; POLYMETHYL METHACRYLATE; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RANK LIGAND; SIGNAL TRANSDUCTION; TACROLIMUS;

EID: 56749107320     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20714     Document Type: Article

References (40)

1. Abu-Amer Y. 2003. Mechanisms of inflammatory mediators in bone loss diseases. In: Rosier RN, Evans CH, editors. Molecular biology in orthopedics. Rosemont, IL: AAOS; p 229-239.
2. Abu-Amer Y, Darwech I, Clohisy JC. 2007. Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 9:S6.
3. Akatsu T, Tamura T, Takahashi N, et al. 1992. Preparation and characterization of a mouse osteoclast-like multinucleated cell population. J Bone Min Res 7:1297-1306.
4. Merkel KD, Erdmann JM, McHugh KP, et al. 1999. Tumor necrosis factor-α mediates orthopedic implant osteolysis. Am J Pathol 154:203-210.
5. Ritchlin CT, Schwarz EM, O'Keefe RJ, et al. 2004. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskelet Neuronal Interact 4:276-284.
6. Horowitz SM, Purdon MA. 1995. Mechanisms of cellular recruitment in aseptic loosening of prosthetic joint implants. Calcif Tissue Int 57:301-305.
7. Purdue PE, Koulouvaris P, Potter HG, et al. 2007. The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 454:251-261.
8. Hallab NJ, Anderson S, Stafford T, et al. 2005. Lymphocyte responses in patients with total hip arthroplasty. J Orthop Res 23:384-391.
9. Arora A, Song Y, Chun L, et al. 2003. The role of the TH1 and TH2 immune responses in loosening and osteolysis of cemented total hip replacements. J Biomed Mater Res Part A 64:693-697.
10. Ritchlin CT, Haas-Smith SA, Li P, et al. 2003. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821-831.
11. Hynes DR, Crotti TN. 2003 Regulation of bone lysis in inflammatory diseases. Inflammopharmacology 11:323-331.
12. Jones DH, Kong YY, Penninger JM. 2002. Role of RANKL and RANK in bone loss and arthritis. Ann Rheumatic Dis 61:ii32-ii39.
13. Khosla S. 2001. Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050-5055.
14. Wei S, Kitaura H, Zhou P, et al. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282-290.
15. Abu-Amer Y. 2005. Advances in osteoclast differentiation and function. Curr Drug Targets Immune Endocr Metab Disord 5:347-355.
16. Takayanagi H, Kim S, Koga T, et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901.
17. Takayanagi H. 2005. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170-179.
18. Clohisy J, Teitelbaum S, Chen S, et al. 2002. TNF mediates PMMA particle-induced NF-kB activation in osteoclast precursor cells. J Orthop Res 20:174-181.
19. Clohisy J, Roy B, Biondo C, et al. 2003. Direct inhibition of NF-kB blocks bone erosion associated with inflammatory arthritis. J Immunol 171:5547-5553.
20. Clohisy J, Hirayama T, Frazier E, et al. 2004. NF-kB signaing blockade abolishes implant particle-induced osteoclastogenesis. J Orthop Res 22:13-20.
21. Abu-Amer Y, Faccio R. 2006. Therapeutic approaches in bone pathogeneses: targeting the IKK/NF-kB axis. Future Med 1:133-146.
22. Dai S, Hirayama T, Abbas S, et al. 2004. The IkB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279:37219-38222.
23. Clohisy JC, Yamanaka Y, Faccio R, et al. 2006. Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and calvarial inflammatory osteolysis. J Orthop Res 24:1358-1365.
24. Hogan PG, Chen L, Nardone J, et al. 2003. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17:2205-2232.
25. Yamanaka Y, Abu-Amer Y, Faccio R, et al. 2006. Map kinase c-JUN N-terminal kinase mediates PMMA induction of osteoclasts. J Orthop Res 24:1349-1357.
26. Abu-Amer Y. 2001. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kB. J Clin Invest 107:1375-1385.
27. Abbas S, Clohisy JC, Abu-Amer Y. 2003. Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J Orthop Res 21:1041-1048.
28. Sabokbar A, Pandey R, Athanasou NA. 2003. The effect of particle size and electrical charge on macrophage-osteoclast differentiation and bone resorption. J Mater Sci Mater Med 14:731-738.
29. Neale SD, Athanasou NA. 1999. Cytokine receptor profile of arthroplasty macrophages, foreign body giant cells and mature osteoclasts. Acta Orthop Scand 70:452-458.
30. Gallo J, Kamínek P, Tichá V, et al. 2002. Particle disease. A. comprehensive theory of periprosthetic osteolysis: a review. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, vol. 146, p 21-28.
31. Haynes DR, Crotti TN, Zreiqat H. 2004. Regulation of osteoclast activity in peri-implant tissues. Biomaterials 25:4877-4885.
32. Clohisy J, Frazier E, Hirayama T, et al. 2003. RANKL is an essential cytokine mediator of PMMA particle-induced osteoclastogenesis. J Orthop Res 21:202-212.
33. Asagiri M, Sato K, Usami T, et al. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202:1261-1269.
34. Aramburu J, Yaffe MB, López-Rodríguez C, et al. 1999. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285:2129-2133.
35. Ikeda F, Nishimura R, Matsubara T, et al. 2004. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114:475-484.
36. Tang G, Minemoto Y, Dibling B, et al. 2001. Inhibition of JNK activation through NF-kappaB target genes. Nature 414:313-317.
37. Meyer C, Wang X, Chang C, et al. 1996. Interaction between c-Rel and the mitogen activated protein kinase kinase kinase 1 signaling cascade in mediating kB enhancer activation. J Biol Chem 271:8971-8976.
38. Macian F. 2005. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 5:472-484.
39. Macián F, López-Rodríguez C, Rao A. 2001. Partners in transcription: NFAT and AP-1. Oncogene 20:2476-2489.
40. Macián F, García-Rodríguez C, Rao A. 2000. Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J 19:4783-4795.